TRELEGY demonstrated improvements across multiple endpoints vs SYMBICORT TURBUHALER 400/121*
TRELEGY demonstrated improvements across multiple endpoints vs SYMBICORT TURBUHALER 400/121*

Help patients breathe better with TRELEGY
Lung Function Improvement
Quality-of-life Improvement
Exacerbation Reduction
Adverse Events
TRELEGY demonstrated significant 171 mL lung function improvement vs SYMBICORT TURBUHALER 400/121*
Co-primary endpoint: change from baseline in trough FEV1 at Week 241,4


*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.2,3
TRELEGY significantly improved quality of life vs SYMBICORT TURBUHALER 400/121*
Patients taking TRELEGY were more likely to show an improvement in quality of life at Week 24 vs SYMBICORT TURBUHALER 400/12,* as measured by SGRQ.1
- SGRQ is a validated, respiratory disease-specific, patient-reported instrument that assesses symptoms, activities, and impact on daily life domains5
*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.2,3
Co-primary endpoint: change from baseline in SGRQ total score at Week 241


TRELEGY demonstrated a 2.2† greater reduction from baseline in SGRQ total score vs SYMBICORT TURBUHALER 400/121* (P<0.001).
† Reflects rounding.
Supporting analysis: SGRQ responder rate‡ at Week 24.1
Analysis was not controlled for multiplicity.
(OR: 1.41; 95% CI: 1.16, 1.70)
50% of patients taking TRELEGY responded to the SGRQ vs 41% for SYMBICORT TURBUHALER 400/12.1*
*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.2,3
‡Responder rate is the percentage of patients with a response, defined as a decrease from baseline of 4 or more in SGRQ total score.1
Secondary endpoint: annual rate of moderate to severe exacerbations1
Endpoint was not adjusted for multiplicity


TRELEGY demonstrated a 35% reduction in the annual rate of moderate to severe exacerbations vs SYMBICORT TURBUHALER 400/12.1*
This study included patients who had received triple therapy (ICS + LABA + LAMA) before entering and were stepped down to the comparator arm (ICS/LABA).1
Exacerbation severity criteria: Moderate if treatment with systemic corticosteroids and/or antibiotics was required and severe if hospitalization was required.1
*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.2,3
From the 24-week, non-US FULFIL trial, the most commonly reported adverse events with ≥2% incidence were1:
From the 24-week, non-US FULFIL trial, the most commonly reported adverse events with ≥2% incidence were1:
Adverse Events | TRELEGY 100 (n=911) % |
SYMBICORT TURBUHALER 400/12* (n=899) % |
Nasopharyngitis | 7 | 5 |
Headache | 5 | 6 |
URTI | 2 | 2 |
COPD§ | 2 | 3 |
Back pain | 2 | 2 |
Arthralgia | 2 | 1 |
Pneumonia | 2 | <1 |
Pharyngitis | 2 | 1 |
§Signs, symptoms, or progression of COPD is more severe than expected for the patient’s condition.
In the non-US FULFIL trial: Incidence of Pneumonia (Adverse Events of Special Interest)1
In the non-US FULFIL trial: Incidence of Pneumonia (Adverse Events of Special Interest)1
TRELEGY 100 % |
SYMBICORT TURBUHALER 400/12* % |
|
24 Weeks |
(n=911) 2.2 |
(n=899) 0.8 |
52 Weeks (extension population) (extension population) |
(n=210) 1.9 |
(n=220) 1.8 |
*SYMBICORT TURBUHALER 400/12 is a non-US formulation that delivers budesonide/formoterol 320/9 and is administered via 1 inhalation taken twice daily.2,3
¶Signs, symptoms, or progression of COPD is more severe than expected for the patient's condition.
Review a head-to-head trial of TRELEGY in adult patients with ASTHMA.